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A recombinant fowlpox virus (rFPV-ORF2ORF1-P12A) containing the open reading frame ORF2)/ORF1 
DNAs of the porcine circovirus 2 (PCV2) (strain, Inner Mongolia) and foot-and-mouth disease virus 
(FMDV) capsid polypeptide of O/NY00 was evaluated for its abilities to induce humoral and cellular 
responses in piglets. In addition, we examined its abilities to protect cell cultures against a homologous 
virus challenge. To approach the feasibility of different united ways of immunization, the recombinant 
fowlpox virus rFPV-ORF2ORF1-P12A and the recombinant DNA plasmid pVAX1-IL18-ORF2ORF1 were 
used to immunize the pigs in “prime-boost”programme. We observed that priming the pigs with DNA 
plasmid pVAX1-IL18-ORF2-ORF1, followed by boosting with the recombinant virus rFPV-ORF2ORF1-
P12A produced partially cellular immunity and humoral immunity. Control groups were inoculated with 
wild-type fowlpox virus (wtFPV) and phosphate buffer saline (PBS). All animals vaccinated with rFPV-
ORF2ORF1-P12A developed specific anti-PCV2/anti-FMDV enzyme-linked immunosorbent assay 
(ELISA) and neutralizing antibodies and also showed T lymphocyte proliferation response. The 
antibody level produced by PCV2 was lower than that of O type FMDV to 1:20 and 1:200 respectively. 
We examined specific cytotoxic T lymphocyte (CTL) production in pigs serum and T lymphocytes (CD4, 
CD8, and CD4/CD8 double positive T cells) in the peripheral blood. First inoculating pVAX1-IL18-
ORF2ORF1 and then rFPV-ORF2ORF1-P12A, had considerably higher CD4+, CD8+ and CD4+CD8+ T 
lymphocytes subgroups compared with the control groups. Whether the ratio between effective cells 
and target cells was 50:1 or 25:1, the specific CTL of experimental groups had much more significant 
differences with the control (FPV), even still the group of priming nucleic acid vaccine boosting 
recombinant virus had the bravest cytotoxicity of specific CTL. Moreover, the E/T ratio of 50:1 was more 
excellent. Following infection respectively with a mixture of a pathogenic strain of PCV2 (strain, Inner 
Mongolia)/FMDV (O/NY00) and neutralizing antibody, PK15 cells (BHK21) inoculated with recombinant 
fowlpox virus (rFPV) showed less (P < 0.05) yellow-green fluorescence and cytopathogenesis, 
suggesting the establishment of partial protection against PCV2/FMDV infection. The results show that 
the immunization programme here, in which pVAX1-IL18-ORF2ORF1 DNA vaccine was inoculated firstly 
and rFPV-ORF2ORF1-P12A was followed, is viable and indicates the potential use of a fowlpox virus-
based recombinant vaccine for the control and prevention of PCV2/FMDV infections.  
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persistent contaminant of the porcine kidney cell line PK-
15 (Tischer et al., 1982). PCV1 is a ubiquitous virus that 
does not cause any disease in piglets (Allan et al., 1995; 
Tischer et al., 1986). PCV2 is associated with clinical 
diseases in  pigs  (Kennedy  et al.,  2000;  Meehan  et al.,  





Post-weaning multisystemic wasting syndrome 
(PMWS), an emerging disease in pigs, is caused by 
PCV2 (Ellis et al., 1998; Kennedy et al., 2000; Ellis et al., 
1999). This PMWS and other porcine circovirus 
associated diseases (PCVAD) have caused severe 
economical losses for swine farmers and the pig industry 
worldwide. The exact mechanisms of how PCV2 
contributes to the clinical manifestation of PCVAD are 
poorly understood and might include host and viral 
genetic determinants (Opriessnig et al., 2006), the 
presence of other infectious agents (Dorr et al., 2007), or 
environmental factors. However, evidence suggests that 
its manifestation requires coinfection with a pathogen 
such as porcine parvovirus (PPV) (Ellis et al., 2000) or a 
similar immune stimulant (Krakowka et al., 2001), 
stressor, or cofactor.  
PMWS mainly affects 5 to 16 week-old pigs (Allan et 
al., 2000; Harding and Clark, 1997; Segales et al., 2004). 
The characteristic clinical signs of PMWS include pro-
gressive weight loss, dyspnea, enlargement of lymph 
nodes, diarrhea, pallor, and jaundice (Allan et al., 2000; 
Segales et al., 2004). PMWS, a new emerging swine 
disease worldwide since its first identification in Canada 
in 1991 (Allan et al., 2000; Chae et al., 2004), is now 
endemic in many pig-producing countries and causes a 
potential economical impact on the swine industry 
worldwide.  
PCV is an icosahedral, nonenveloped virus, and 
measures 17 nm in diameter. The genome of PCV is a 
single-stranded circular DNA of about 1.76 kb. PCV 
genome contains at least two potentially functional open 
reading frames (ORFs): ORF1 (930 bp) encodes the Rep 
protein involved in viral replication and ORF2 (690 bp) 
encodes the immunogenic capsid protein. 
The overall DNA sequence homology within the PCV1 
or PCV2 isolates is greater than 90%, while the homology 
between PCV1 and PCV2 isolates is 68 to 76%. Two 
major open reading frames (ORFs) have been 
recognized for PCV; ORF1, called the rep gene, which 
encodes a 35.7-kDa protein involved in virus replication 
(Mankertz et al., 1998), and ORF2, called the cap gene, 
which encodes the major 27.8-kDa immunogenic capsid 
protein (Cheung, 2003; Nawagitgul et al., 2002; 2000). In 
addition to the replicase ORF1 and the capsid protein 
ORF2, the virus genome is predicted to contain another 
five potential ORFs encoding proteins larger than 5 kDa 
(Meehan et al., 1997). Whether these potential ORFs are 
expressed or not and whether the expressed proteins are 
essential for viral replication remain to be elucidated. 
The use of fowlpox virus vectors for heterologous 
antigen delivery has been explored in a variety of fields 
(Jiang et al., 2005; Tine et al., 2005; Karaca et al., 
2005).Despite the fact that their replication is restricted to 
avian species, attenuated strains of the fowlpox virus 
have shown to be efficacious and extremely safe vectors 





recombinants into mammalian cells has in fact resulted in 
the expression of the foreign gene and induction of 
protective immunity (Karaca et al., 2005). This obser-
vation shows that favorable immune responses could be 
induced in the absence of productive replication, while 
eliminating the potential for dissemination of the vector 
within the vaccinator and the spread of the vector to non-
vaccinated contacts or to the general environment (Taylor 
and Paoletti, 1988; Pastoreta and Vanderplasschen, 
2003). However, the use of the fowlpox virus as a 
vaccine vector for recombinant PCV2 vaccines has not 
been previously investigated. 
In this study, the immune responses of pigs inoculated 
with a recombinant fowlpox virus vaccine by different 
vaccination schemes were evaluated. We examined the 
ability of priming the recombinant fowlpox viruses (rFPV-
ORF2ORF1-P12A) and/or boosting the recombinant 
plasmid (pVAX1-IL18-ORF2ORF1) to elicit PCV2-specific 
immune responses and protective efficacy in pigs. Our 
results indicate that the recombinant fowlpox virus, rFPV-
ORF2ORF1-P12A, may be an effective vaccine affording 
protection to pigs against PCV2 challenge. 
 
 
MATERIALS AND METHODS 
 
Viruses cells and plasmids 
 
The wild type strain of the fowlpox virus (wtFPV) is an attenuated 
vaccine produced by the Animal Pharmaceutical Factory of Nanjing 
(Nanjing, China). The recombinant fowlpox virus rFPV-ORF2ORF1-
P12A containing the ORF2/ORF1 DNAs of PCV2 (strain, Inner 
Mongolia) and the foot-and-mouth disease virus (FMDV) capsid 
polypeptide of O/NY00 was previously constructed in our lab. 
wtFPV and rFPV were prepared in chicken embryo fibroblast 
(CEF) cells in MEM supplemented with 10% fetal calf serum (FCS). 
PCV2 (strain, Inner Mongolia) originally isolated from lymph node 
sample of a pig with naturally occurring PMWS (Fenaux et al., 
2002) was preserved and passed to PCV-negative PK-15 cells 
(ATCC CCL33). FMDV O/NY00 was preserved and passed in 
BHK21 cells to obtain a titer of 1 × 10
6.4
 50% tissue culture 
infectious dose (TCID50)/0.01 ml in our lab. We previously 
constructed the recombinant plasmid pUTALP12A encoding the 
capsid polypeptide genes of FMDV O/NY00 and another 
recombinant plasmid, pMD18-T-ORF2ORF1, encoding PCV2 
genes. The recombinant plasmid (pVAX1-IL18-ORF2ORF1) 
encoding the ORF2/ORF1 genes of PCV2 and pig interleukin-18 
mature protein gene was previously constructed. 
 
 
Selection and identification of rFPV-ORF2ORF1-P12A 
 
The fowlpox virus shuttle vector pUTALP12A, which was composed 
of the combined promoter TI-P7.5 (ATI promoter of cowpox virus 
and 20 tandemly repeated mutant P7.5 early promoters of vaccinia 
virus) and the P12A gene controlled by the single promoter (16 
tandemly repeated mutant   P7.5 early promoters of vaccinia virus) 
have been reported previously (Zheng et al., 2006). The plasmid 
pMD18-T-ORF2ORF1 was digested with SmaI to produce an 
ORF2ORF1 fragment that was then inserted into the SmaI site 
under the combined promoter ATI-P7.5 of pUTALP12A, and the 
shuttle vector pUTALORF2ORF1-P12A was obtained. Sub-
sequently, the rFPV-ORF2ORF1-P12A was selected and identified 
as described  previously  (Zheng et al., Ma  et al., 2006). Briefly, the  




Table 1. Immunization in “prime-boost” programme. 
 
Group Code  
Inoculated times and biologic 
1st  i. m(1 day) 2nd  i. m (28 day) 
Controls N PBS PBS 
    
Trials 
M wtFPV wtFPV 
I rFPV-ORF2ORF1-P12A rFPV-ORF2ORF1-P12A 
J rFPV-ORF2ORF1-P12A pVAX1-IL18-ORF2ORF1 




shuttle plasmid pUTALORF2ORF1-P12A and wtFPV were 
cotransfected to 80% confluent CEF cells via liposomes 
(lipofectamine, Invitrogen Corporation). The viruses were collected 
after a cytopathic effect (CPE) appeared. They were then screened 
three times under the presence of 40 µg/mL BudR (5-bromo-2′ 
deoxyuridine, Sigma) and cultured in MEM medium without BudR. 
The individual virus plaque was selected, amplified, and purified 
when CPE appeared, and identified by electron microscope. The 





We brought 40 segregated early weaned crossbred pigs 
approximately 8 to 12 week-old pigs from a PCV2- and FMDV-free 
farm in ChangChun, China. 
 
 
Inoculation of pigs with rFPV 
 
The pigs were divided into five groups (five pigs per control group 
and ten pigs per trial group). Pigs in the respective control groups 
were inoculated intramuscularly with 200 µL phosphate-buffered 
saline (N) and 2 × 10
8
 plaque-forming units (PFU) of wtFPV (M). 
Pigs in the trial groups (I J and K) were inoculated intramuscularly 
with the same dose of rFPV-ORF2ORF1-P12A (2 × 10
8
 PFU) or 
200 µg pVAX1-IL18-ORF2ORF1, respectively. All groups were 
boosted with an equivalent dose at 28 days post-inoculation (dpi) 
(Table1). Blood samples were collected from each pig pre-
inoculation and every week post-inoculation. 
 
 
Evaluation of the humoral immune response 
 
Evaluation of the humoral immune response to PCV2 
 
Indirect enzyme-linked immunosorbent assays (I-ELISAs) were 
performed (according to the protocol of the PCV2-Diagnosis-Assay 
kit provided by the Veterinary College, Huazhong Agricultural 
University) on pig serum to measure the amount of anti-PCV2 
antibodies present in each sample. Briefly, 96-well flat-bottom 
plates coated with the ORF2 protein of PCV2 were incubated in 
duplicate with 20-fold dilutions of test sera for 30 min at 37°C. 
Peroxidase-conjugated anti-pig IgG conjugate was then added for 
30 min at 37°C, followed by addition of the substrates (each 50 µl). 
After 10 min in the dark at room temperature, the color reaction was 
terminated with 50 µl of dense H2SO4, and the absorbance at 630 
nm was determined using an ELISA plate reader within 15 min. 
Serum samples from all pigs were analyzed for neutralizing 
antibodies by using a neutralization assay (Tischer et al., 1986) with 
a monolayer of PK-15 cells. Sera were inactivated at 56°C for 30 
min and 2-fold dilutions (in duplicate) and 50 µL of each sample or 
control serum was added to the well at     the end of each row of a 
24-well tissue culture plate. Samples were then serially diluted 
twofold across the plates. Further, 50 µl PCV2 suspension of 200 
IU/150 µl (1 IU = amount of virus causing specific immuno-
fluorescence in 1 cell/well) was added to each well and the plate 
was vortexed for 1 min. After incubation at 37°C for 90 min, this 
mixture was inoculated into 1-day PK-15 cell cultures in each well. 
After incubation for 1 h (37°C; 5% CO2), cultures were washed and 
growth medium (MEM + 5% FCS) was added. 4 h later, cultures 
were treated with D-glucosamine (Sigma) and thereafter incubated 
in growth medium. 24 h after inoculation, a period in which PCV2 
antigen resulting from a secondary infection of cells by progeny 
virus has not yet been formed, cultures were fixed and tested for 
the presence of specifically fluorescent cell nuclei by the indirect 
fluorescent antibody (IFA) test using rabbit anti-PCV2 antiserum. 
The neutralizing titer was defined as the highest serum dilution 




Evaluation of the humoral immune response to FMDV   
 
I-ELISAs were performed (Ma et al., 2008) on pig serum to 
measure the amount of anti-FMDV antibodies present in each 
sample. Serum samples from all pigs were analyzed for neutralizing 
antibodies using a neutralization assay with a monolayer of BHK21 
cells (Cedillo-Barron et al., 2001; Yu and 221Cui, 1997). The 




Evaluation of the cellular immune response to immunization 
 
T lymphocyte proliferation assay 
 
3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium-bromide) 
(MTT) assay was performed to determine T lymphocyte 
proliferation. Peripheral blood (taken at 14 and 42 dpi, respectively) 
from each pig was collected into tubes containing sodium heparin 
as an anticoagulant. Peripheral blood mononuclear cells (PBMCs) 
were isolated from each blood sample by Ficoll-Hypaque density 
gradient centrifugation and resuspended in RPMI 1640 medium 
with 10% FCS. The MTT assays (Zheng et al., 2006) were carried 
out in triplicate cultures (200 µL 2 × 10
6
 cells/mL) in 96-well flat-
bottom plates (Costar). T lymphocytes were stimulated with 2 
µg/mL of recombinant VP1 protein, or 1:100 live O/NY00, or 1 
µg/mL of Concanavalin A. The plate was incubated at 37°C for 45 
h, followed by incubation with MTT for 3 h and addition of 150 µL 
DMSO to every well to dissolve the deposit. Absorbance was 
determined at 570 nm and results were expressed as stimulation 
index (SI) (cpm sample/cpm medium alone). 












 T lymphocytes 
subtypes 
 
At 21 and 42 dpi, peripheral blood was collected from each pig. The 
isolation method of PBMCs was the same as described in 
previously. PBMCs were adjusted to 1 × 10
6 
cells/mL. After 
centrifugation, the supernatants were discarded and the remaining 
cell pellets were resuspended with 50 µL of monoclonal antibodies 
(MAb) against CD4 or CD8 (PE-labeled anti-pig CD4a and FITC-
labeled anti-pig CD8a, BD Biosciences Pharmingen) and incubated 
on ice for 30 min. After washing, the cells were analyzed with the 
FACScan cytometer (Becton Dickinson) at an excitation wavelength 





At 42 dpi, peripheral blood was collected from each pig. The 
isolation method of PBMCs was the same as described in above. 
The PBMCs were resuspended in RPMI 1640 medium 
supplemented with 10% FCS, 2 µg/mL Concanavalin A (Sigma), 
and 10 U/mL of IL-2 and cultured in vitro as the effector cells. 
A modified PK15 cell line, which stably expressed the ORF2 
protein of PCV2, was previously constructed by transfecting the 
cells with the mammalian expression plasmid pDisplay-ORF2 (data 
not shown). The stimulator cells were harvested and treated with 25 
µg/mL mitomycin C at 37°C in 5% CO2 for 2 h. Subsequently, the 
cells were pelleted and washed four to five times with RPMI 1640 
medium. The effector cells (4 × 10
7
 cells) were incubated with 
stimulator cells at an effector-stimulator ratio of 50:1 or 25:1 for 
three days at 37°C in 5% CO2. 
To measure the specific lysis of these target cells, the lactate 
dehydrogenase (LDH) release assay was performed according to 
the manufacturer’s protocol. In 96-well round-bottom plates, target 
cells were incubated with effector cells at various effector-target 
ratios for 4 h in phenol red-free RPMI 1640 containing 3% FCS. 
The supernatant (100 µL/well) was then transferred to 96-well 
plates, and lysis was determined by measuring LDH release using 
a non-radioactive cytotoxicity assay kit (Promega Corporation, 
USA). The absorbance values of the supernatants were recorded at 
490 nm on an ELISA microplate reader. 
The percentage of specific lysis of PK15 target cells for a given 
effector cell sample was calculated by the following formula: 
specific lysis = (OD of experimental LDH release - OD of effector 
cell spontaneous LDH release - OD of target cell spontaneous LDH 
release)/(OD of maximum target LDH release - OD of target 
spontaneous LDH release) ×100%. All determinations were 













 subtype T 
lymphocytes, and SI of inoculated pigs were compared to those of 
control animals using the analysis of variance and t-tests. A P value 





Humoral immune response to inoculation with rFPV 
Specific anti-PCV2 antibody titers (AT) of rFPV-ORF2-
ORF1-P12A vaccinated pigs were not significantly 
different (P > 0.05) compared with   M/N control groups 
from 7 dpi to 42 dpi. However, the AT increased gradually 





difference between the 3 prime-boost immunization 
regime groups. The amount of specific anti-FMDV anti-
body in the rFPV-vaccinated groups was significantly 
increased compared with the M and N inoculated groups. 
However, the antibody responses of the I, J and K 
vaccinated groups were not significantly different (Figure 
1). 
The sera from inoculated pigs were tested for their 
ability to neutralize PCV2/FMDV in PK-15 cells and BHK-
21 cells. At 14 and 42 dpi, sera from rFPV-inoculated 
pigs showed PCV2/FMDV neutralizing activity (Table 2). 
The titer of neutralizing antibodies in rFPV-inoculated 
pigs ranged from 1:26.6 to 1:46.6 and 1:26.91 to 76.11. 
The sera from wtFPV-inoculated pigs showed no 
PCV2/FMDV-neutralizing activity. There was a higher 
antibody titer of PCV2 in the group primed with rFPV-
ORF2ORF1-P12A and boosted with pVAX1-IL18-
ORF2ORF1, while the antibody titer of FMDV in the 
group primed with rFPV-ORF2ORF1-P12A and boosted 
with rFPV-ORF2ORF1-P12A was the highest. 
 
 
Cell-mediated immune response 
 
T lymphocyte proliferation response of pigs 
 
Pigs in the rFPV-ORF2ORF1-P12A-vaccinated/ inocu-
lated groups showed a specific T lymphocyte proliferation 
response (stimulated with live virus or purified 
recombinant VP1 protein) and a relatively weak non-
specific proliferation response (stimulated with ConA). In 
contrast, pigs in the wtFPV/PBS-inoculated group only 
developed a weak non-specific T lymphocyte proliferation 
response. Analysis of the specific T lymphocyte 
proliferation response showed that the J-inoculated group 
had a higher SI, but no significant difference was 
observed between the tested groups (Table. 3). 
 
 
Analysis of T lymphocytes subtypes 
 
Peripheral blood lymphocytes were analyzed by flow 
cytometry at 21 and 42 dpi, respectively. At 21 dpi, there 










lymphocytes of the rFPV-vaccinated groups and that of 
the wtFPV/PBS-inoculated   groups. At 42 dpi, the 
percentage numbers of CD8
+
 T lymphocyte subgroups of 
the rFPV-vaccinated groups were higher (P < 0.05) 
compared with the wtFPV/PBS-inoculated groups. The J-
vaccinated group was higher than the other tested groups 
but no significant difference was observed (Figure 2). 
 
 
CTL activity of immunized pigs 
 
The   cytotoxic   activities   of   the  inoculated  pigs  were 






Figure 1. The antibody level of anti-FMDV (a) and anti-PCV2 (b) after immunization. Sera from all 
pigs were sampled regularly and tested for antibodies against FMDV (1:200 dilution) and PCV2 




Table 2. Maximum dilution of neutralizing antibodies in sera of pigs inoculated with rFPV 
 
Immune group 
0 dpi 14 dpi 42 dpi 
FMDV PCV2 FMDV PCV2 FMDV PCV2 
I 1.82 1.82 76.11 30.2 76.12 27.0 
J 1.82 1.82 38.05 46.6 26.91 40.7 
K 1.82 1.82 53.82 26.6 38.05 37.2 
M 1.82 1.82 <2 <2 <2 <2 
N 1.82 1.82 <2 <2 <2 <2 
 
Neutralizing antibody titers were analyzed at 14 and 42 days post-inoculation (dpi). Serum samples were obtained 
from five pigs of each group.  
                                                                     
                                                                   (a) 






























































Table 3. Specific T lymphocyte proliferation assay. 
 
Group 
      Stimulate index 
(Vp1) protein (O FMDV) live virus ConA Control 
14 days 42 days 14 days 42 days 14 days 42 days 14 days 42 days 
I 1.143 1.448 1.888* 1.197 0.941 0.873 0.217 0.39 
J 1.337* 1.258 2.078* 1.205 0.988 1.653* 0.287 0.42 
K 1.034 1.337 1.889* 1.406 1.017* 1.547* 0.268 0.405 
M 0.986 1.225 1.222 1.167 0.914 0.873 0.217 0.39 
N 0.927 1.000 1.011 1.000 0.901 1.000 0.193 0.26 
 
T lymphocyte proliferation responses of pigs stimulated by live virus, purified recombinant VP1 protein and ConA, respectively; 














 T lymphocytes of different prime-boost immunization groups. This test was 




measured by the non-radioactive LDH release assay and 
the specific lysis rates are shown in Figure 3. All tested 
vaccines groups elicited specific CTL cytotoxic activities 
compared with wtFPV- and PBS-inoculated groups (P < 
0.05). The   specific lysis rate of the J or K group was 





The vaccine potential of recombinant fowlpox viruses is 
well established. It has been successfully employed in 
the development of recombinant FMD and of recom-
binant porcine reproductive and respiratory syndrome 
(PRRS) vaccines(Zheng et al., 2006; Shen et al., 2007). 
Recombinant fowlpox virus vaccines offer significant 
advantages over the traditional virus-inactivated vaccines 
or recombinant proteins, because the antigen is expres-
sed intracellularly in the immunized animal. Therefore, 
the processing and presentation of the viral epitope 
occurs in a way that is similar to a natural infection. 
Moreover, the fowlpox virus vector is a non-replication 
vector when used in mammals, so it does not carry the 
risk of replication associated with Vaccinia virus vaccines 
(Pastoreta and Vanderplasschen, 2003). Therefore, we 
attempted to develop a recombinant PCV2 vaccine on 
the basis on the fowlpox virus vector. In this work, an 
experimental immunization regimen was developed and 
tested against PCV2. Piglets coinfected with PCV2 and 
FMDV developed a more severe clinical disease and 
PCV2-associated lesions than piglets infected with PCV2 
(data not shown). Thus, the gene fragment P12A of 
FMDV (Berinsteina et al., 2000) in addition to ORF2-
ORF1 of PCV2 was chosen and used to construct the 
recom-binant fowlpox virus. The recombinant fowlpox 
virus coexpressing ORF2ORF1 (PCV2) and P12A 
(FMDV) was inoculated in pigs and tested in a protection-

















































Figure 3. Specific lysis of target cells by restimulated effector cells from the immunized pigs. Effector-to-target cell ratios are 
indicated in different colors. The percent specific lysis is demonstrated on the vertical axis. This test was performed at 42 dpi. (a) 
specific CTL activity for PCV; (b) specific CTL activity for FMDV; N=PBS group; M=wtFPV group; I=rFPV-ORF2ORF1-P12A/rFPV-




ORF2ORF1 (PCV2) and P12A (FMDV) can induce a 
partial protective immunity. This finding suggests that this 
experimental    method of antigen presentation may be 
useful for future protection studies of these and other 
possibly protective PCV2 (FMDV) antigens, alone or in 
combination. 
A genetic engineering vaccine against PCV2 is not yet 
available, although an experimental vaccine based on a 
chimeric virus of PCV1 and PCV2 was very promising 
(Fenaux et al., 2004; 2003). Engineering vaccine design 
for manipulating antigen presentation and processing 
pathways is one of the most important aspect that can be 
easily handled in the DNA vaccine technology. If an 
antibody response is the goal, it is clearly desirable to 
direct antigen expression to the endo plasmic 
reticulum(ER), in which folding and secretion can occur. 
An appropriate leader (signal) sequence can achieve this. 
For induction of CTLs, addition of genes encoding 
molecules such as ubiquitin, aimed to enhance 
degradation and peptide production in the proteasome, 
can be effective. Similarly, targeting expression to 
different subcellular pathways such as the endosome or 
lysosome can amplify CD4+ T cell responses. 
Vaccination schedules based on combined prime-boost 
regimens using different vector systems to deliver the 
desired antigen (that is heterologous prime- boost immu-
nization regimen) appear to be a successful improvement 
in DNA vaccine platform. Actually, prime-boost regimens 
have shown promise in eliciting greater immune response 
in humans compared with DNA vaccination alone 
(Daniela et al, 2010). 
The heterologous prime-boost vaccination regimen 
exploits the ability of the immune system to generate a 
large number of secondary antigen-specific T cells. 
Following a priming immunization, a proportion of the 
antigen-specific T cell populationtrans forms into antigen-
specific memory T cells, which have the ability to expand 
rapidly up on encounter with the same antigen a second-
time round. 
Since the priming and boosting vectors are different, 
and induction of effective immunity are becoming clear, 
this strategy allows for greater expansion of the disease 
antigen-specific T cell populations. To date, heterologous 
prime-boost regimens are among the most potent 
strategies to induce cellular immune responses. Com-
pared to homologous prime-boost approach with the 
same DNA vaccine, boosting a primary response with a 
heterologous vector will result in 4 to 10-fold higher T cell 
responses (Daniela et al, 2010). Though prime-boost 
regimens was adopted in the study, the antibody levels in 
trail groups still had no statistics senses compared with 
the control ones. So, the recombinant vaccine is to 
further be improved. 
In this study, it is surprising to find that the antibody 
level of anti-PCV2 was not different from the control 
(Figure 1b). It is possible that only the four 
immunodominant regions of ORF2-PCV2 and one of 





































     
 





    
                             























can be thought that ORF1 protein has no immune 
reactivities. In addition, for the coated ORF2-PCV2 
protein used by I-ELISA which was gained by prokaryotic 
expression, its naturally biological activity may be another 
factor to affect immune reactivities. Whether the anti-
ORF2-PCV2 antiserum generated from a regional PCV2 
strain could recognize the same epitopes in strain from 
other countries is not yet known and such experiments 
would provide information about epitope variability among 
PCV2 strains. We found that relatively high levels of 
neutralizing antibody and protection against PCV2/FMD 
were induced in all rFPV-vaccinated groups. Pigs 
inoculated with rFPV developed neutralizing antibodies 
with titers ranging from 1:26.6 to 1:46.6 (PCV2) and 
1:26.9 to 76.11 (FMDV), (Table 1) which indicate that 
rFPV expressing ORF2ORF1 and P12A induces PCV2- 
and FMDV-neutralizing antibodies in pigs. Because 
TCID50 was here used to assess the titers of neutralizing 
antibodies, it is necessary to further examine the result 
depending on the experimental piglets. Although it is 
generally accepted that protective immunity to FMDV is 
principally due to neutralizing antibodies, the cellular 
immune response provides an essential regulatory role in 
the induction and expression of the serological response. 
In order to evaluate the rFPV-induced PCV2 (FMDV)-
specific T cell response, we applied the MTT assay to 
measure the T lymphocyte proliferation response. 
Analysis of the specific T lymphocyte proliferation res-
ponse showed there was a significant difference (P < 
0.05) between the rFPV-ORF2ORF1-P1 groups and the 
control groups, and the SI of the prime-boost vaccination 
with rFPV-ORF2ORF1-P12A and the recombinant 
plasmid pVAX1-IL18-ORF2ORF1 was higher than in the 
other groups.  
Although a higher SI was achieved with the recom-
binant VP1 protein, the index was still relatively lower 
compared with the live viruses. Since wasted pigs always 
had a lower proportion of the CD4
+
 cell subsets and a 






 cells was 
observed in   PCV2-positive pigs (Darwich et al., 2002), 
the results of T lymphocyte subgroup analysis indicate 
that at 42 dpi, the percentage numbers of CD8
+
 T 
lymphocytes subgroups of the rFPV-vaccinated groups 
were higher (P < 0.05) compared with the wtFPV/PBS-
inoculated groups. The percentage numbers of CD8
+
 T 
lymphocyte subgroups in the rFPV-ORF2ORF1-P12A/   
pVAX1-IL18-ORF2ORF1-vaccinated group was higher 
than in the other tested groups, but no significant 
difference was observed (Fig. 2). In addition, at 21 and 
42 dpi, the percentage numbers of the CD8
+
 T lympho-







 T    lymphocyte subgroups. Moreover, 
priming with rFPV-ORF2ORF1-P12A or boosting with the 
recombinant plasmid pVAX1-IL18-ORF2ORF1 led to an 
augmented CD8
+





 T lymphocyte subgroups was 





that rFPVs have the ability to increase cytotoxic res-
ponses and improve memory and/or effector cell 





lymphocytes subgroups were positively related to the 
pigs' growth . 
The CTL assay resulted in statistically noticeable 
augmentation of specific-CTL activity (PCV2/FMDV) in 
rFPV-vaccinated groups compared to wtFPV/PBS at 25:1 
and 50:1 effector-to-target ratios. This finding also elicited 
that rFPV-ORF2ORF1-P12A indeed promoted the Th2-
mediated immune response consistent with the CD8
+
 cell 
subsets being mainly responsible for cytotoxic responses. 
Additional evidence has been indicated because prime-
boost with the recombinant plasmid pVAX1-IL18-
ORF2ORF1 and rFPV-ORF2ORF1-P12A at a 50:1 ratio 
for both PCV2 and FMDV showed a statistically 
significant increase in the CTL-specific immunogenicity 
over the other two regimen. Altogether, it is clear that the 
cellular immune response of rFPV-ORF2ORF1-P12A 
were better than the antibody titers for PCV2, but rFPV-
ORF2ORF1-P12A induces good neutralizing antibodies 
that is beyond what is expected. Although results of the 
immune response and viral challenge show that the 
rFPV-ORF2ORF1-P12A-inoculated group developed a 
stronger immune response and better protection, it would 
be advisable to focus future studies on how PCV2 acts 
on the immune systems of infected pigs. This would allow 
a more effective use of rFPV-ORF2ORF1-P12A by 
different inoculation schemes. In summary, in this study, 
we show that pigs immunized with rFPV-expressing 
ORF2/ORF1 and P12A were able to elicit a partial 
humoral and cellular response. Most importantly, a 
degree of protection was also shown against the 
challenge with a pathogenic strain of PCV2/FMDV. 
Moreover, a heterologous prime-boost    (rFPV-
ORF2ORF1-P12A/pVAX1-IL18-ORF2ORF1 or pVAX1-
IL18-ORF2ORF1/rFPV-ORF2ORF1-P12A) immunization 
strategy was more efficient in inducing a T cell response 
than the homologous prime-boost (rFPV-ORF2ORF1-
P12A/rFPV-ORF2ORF1-P12A).   In   the   PCV2/FMDV 
TCID50 assay, pigs immunized with a heterologous prime-
boost regimen such as rFPV-ORF2ORF1-P12A/pVAX1-
IL18-ORF2ORF1 showed better protection. These 
studies demonstrate that this vaccination strategy may be 
useful and rFPV-ORF2ORF1-P12A could be further 
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